ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has suspended registration of three drug products that do not qualify the criteria of safety, efficacy and quality (SEQ).
The suspended drug products include painkiller tablets of Diclofenac Potassium in strengths of 75 and 100 mg, liquid suspension of anti-ulcer drug Famotidine in strengths of 10mg/5ml and 40mg/5ml, and a combination drug product containing paracetamol, thioridazine and caffeine. In a press release issued here on Saturday, DRAP has advised healthcare professionals, patients and their attendants to desist from prescribing or using these drug products as there is very less data on their SEQ.
ISLAMABAD: The Election Commission has formally sought the deployment of the Pakistan Army and Civil Armed Forces...
ISLAMABAD/KARACHI/LARKANA: The MQM, GDA, and PMLN have rejecteddelimitations in Sindh and accused the provincial...
ISLAMABAD: The National Electric Power Regulatory Authority (Nepra) has disclosed a massive and deliberate trend of...
LAHORE/ISLAMABAD: National Accountability Bureau Chairman Lt-Gen(Retd) Nazir Ahmad Butt has assured the bureaucracy of...
LAHORE: The Satokatla Police have arrested three members of a gang selling human kidneys. At a press conference here...
ISLAMABAD: The International Monitory Funds (IMF) has not yet finalised the exact schedule for the Executive Board...
LAHORE: The Pakistan Muslim League Nawaz (PMLN) has clarified that it will not form an election alliance with the...
ISLAMABAD: Defending him against a barrage of accusations doing the rounds in the media concerning his marriage, PTI...